What is Bluejay Diagnostics, Inc.'s earnings per share (EPS)?

Bluejay Diagnostics, Inc. (BJDX) reported diluted earnings per share of -$15.25 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Bluejay Diagnostics, Inc. (BJDX) Financials

BJDX

FY2025 annual

Net Income -$6.8M +11.3% YoY

EPS (Diluted) -$15.25 YoY not available

Free Cash Flow -$6.2M +23.4% YoY

Operating Cash Flow -$6.1M +22.6% YoY

Market Cap $928K as of Sep 12, 2026

Price / Sales n/m no revenue reported

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book 0.1x on $9.4M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 12, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 12, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 12, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BJDX SEC filings page.

This page shows Bluejay Diagnostics, Inc. (BJDX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI BJDX FY2025 2026-09-05

Development-stage cash consumption remains the dominant mechanic, with financing inflows supporting operations while capital spending stays modest.

In FY2025, operating cash flow of -$6.1M closely tracked the net loss of -$6.8M, while free cash flow of -$6.2M remained near operating cash flow. That combination indicates the loss is largely cash-based, with capital spending—not the main cash drain—accounting for only a small additional outflow.

The operating model remains development-stage: reported revenue was just $249K in FY2022 against $4.2M of research and development, and later filings report no revenue line. Expense intensity therefore says more about current operations than revenue margins do.

FY2025 operating cash flow improved 22.6% from FY2024, yet $7.1M of financing cash flow exceeded the operating outflow, so operations did not fund the business. A current ratio of 4.9x and reported liquidity equal to 10.2 months of latest annual operating outflow describe short-term financial capacity despite continuing losses.

Financial Health Signals

Financial health score not available

Bluejay Diagnostics, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

2/6

Bluejay Diagnostics, Inc. passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality No Cash Backing

N/A

Bluejay Diagnostics, Inc. reported a net loss of $6.8M while operations used $6.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

Bluejay Diagnostics, Inc. reported an operating loss of $7.0M against $839 in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$2.3M

YoY-18.0%

QoQ-21.4%

Bluejay Diagnostics, Inc.'s EBITDA was -$2.3M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 18.0% from the same quarter a year earlier. Against the prior quarter it is down 21.4%.

Net Income

-$2.3M

YoY-18.8%

QoQ-21.1%

Bluejay Diagnostics, Inc. reported -$2.3M in net income in Q2 2026. This represents a decrease of 18.8% from the same quarter a year earlier. Against the prior quarter it is down 21.1%.

EPS (Diluted)

-$1.12

Bluejay Diagnostics, Inc. earned -$1.12 per diluted share (EPS) in Q2 2026.

Revenue

Not reported for Q2 2026.

Cash & Balance Sheet

Free Cash Flow

-$1.6M

QoQ-2.1%

Bluejay Diagnostics, Inc. recorded an outflow of $1.6M in free cash flow in Q2 2026, representing a cash shortfall after capex. Against the prior quarter it is down 2.1%.

Cash & Debt

$9.6M

YoY+116.0%

QoQ+160.5%

Bluejay Diagnostics, Inc. held $9.6M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

Bluejay Diagnostics, Inc. had 4M shares outstanding in Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

-24.7%

YoY+12.3pp

QoQ+21.2pp

Bluejay Diagnostics, Inc.'s ROE was -24.7% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 12.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 21.2 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$1.4M

YoY+61.6%

QoQ+77.1%

Bluejay Diagnostics, Inc. invested $1.4M in research and development in Q2 2026. This represents an increase of 61.6% from the same quarter a year earlier. Against the prior quarter it is up 77.1%.

Capital Expenditures

$143K

QoQ+651.9%

Bluejay Diagnostics, Inc. invested $143K in capex in Q2 2026, funding long-term assets and infrastructure. Against the prior quarter it is up 651.9%.

Share Buybacks

Not reported for Q2 2026.

BJDX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BJDX quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Revenue	N/A	N/A	N/A	N/A	$249K	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	$200K	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	$49K	N/A	N/A
R&D Expenses	N/A	$3.0M-12.2%	$3.5M-39.2%	$5.7M+37.6%	$4.2M+261.7%	$1.1M+117.7%	$527K
SG&A Expenses	N/A	$3.9M+5.9%	$3.7M+1201.7%	$283K-37.2%	$451K-74.8%	$1.8M+200.7%	$596K
Operating Income	N/A	-$7.0M+3.0%	-$7.2M+30.5%	-$10.3M-10.7%	-$9.3M-188.5%	-$3.2M-170.0%	-$1.2M
EBITDA	N/A	-$6.9M+3.0%	-$7.1M+26.6%	-$9.7M-5.5%	-$9.2M-197.0%	-$3.1M-196.8%	-$1.0M
Interest Expense	N/A	$839-99.9%	$823K	N/A	$125K+1862.7%	$6K-89.3%	$59K
Net Income	N/A	-$6.8M+11.3%	-$7.7M+22.5%	-$10.0M-7.1%	-$9.3M-166.5%	-$3.5M-201.2%	-$1.2M
EPS (Basic)	N/A	-$15.25+96.7%	-$456.75+87.4%	-$3631.48-39287.0%	-$9.22-2148.8%	-$0.41	N/A
EPS (Diluted)	—	-$15.25	-$456.75	-$3631.48	-$9.22	-$0.41	N/A
Diluted Shares (Avg)	N/A	449,043	45,848	2,741	1M	9M	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
R&D Expenses	$1.4M+61.6%	$812K+3.4%	N/A	$786K+42.4%	$890K-13.8%	$785K-41.2%	N/A	$552K-60.5%
SG&A Expenses	$911K-16.8%	$1.1M+2.1%	N/A	$831K+2.7%	$1.1M+27.0%	$1.1M+17087.4%	N/A	$809K+4224.6%
Operating Income	-$2.3M-18.3%	-$1.9M-2.6%	N/A	-$1.6M-18.8%	-$2.0M-4.8%	-$1.9M+22.2%	N/A	-$1.4M+41.8%
EBITDA	-$2.3M-18.0%	-$1.9M-2.2%	N/A	-$1.6M-19.5%	-$2.0M-4.8%	-$1.9M+22.3%	N/A	-$1.3M+35.6%
Interest Expense	N/A	N/A	N/A	$200-99.9%	$222-100.0%	N/A	N/A	$186K
Net Income	-$2.3M-18.8%	-$1.9M-2.9%	N/A	-$1.6M-7.8%	-$2.0M+21.0%	-$1.9M+19.9%	N/A	-$1.5M+35.5%
EPS (Basic)	-$1.12+80.1%	-$1.95+85.5%	-$10.63+93.9%	-$1.01-1213.4%	-$5.64-2101.4%	-$13.46+96.6%	-$173.57-9651.1%	-$0.08+99.5%
EPS (Diluted)	-$1.12	-$1.95	-$10.63+93.9%	-$1.01	-$5.64	-$13.46	-$173.57	-$76.94
Diluted Shares (Avg)	2M	984,668	N/A	2M	346,780	138,503	N/A	191,117

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Income Tax.

BJDX Balance Sheet

BJDX quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Total Assets	$7.1M+6.9%	$6.7M+36.7%	$4.9M-64.0%	$13.5M-35.7%	$21.0M+1285.3%	$1.5M
Current Assets	$5.5M+11.5%	$4.9M+52.1%	$3.2M-72.7%	$11.8M-42.9%	$20.7M+1852.4%	$1.1M
Cash & Equivalents	$5.2M+20.1%	$4.3M+94.8%	$2.2M-78.2%	$10.1M-46.9%	$19.0M+1987.7%	$912K
Short-Term Investments	$0	$0	$0	$0	$0	$0
Inventory	N/A	N/A	N/A	N/A	N/A	$85K
Long-Term Investments	$0	$0	$0	$0	$0	$0
Total Liabilities	$1.1M+23.3%	$928K-53.0%	$2.0M-0.3%	$2.0M+210.8%	$637K-88.9%	$5.7M
Current Liabilities	$1.1M+38.1%	$810K-54.3%	$1.8M+8.0%	$1.6M+157.4%	$637K	N/A
Non-Current Liabilities	$25K-78.9%	$118K-41.9%	$202K-40.5%	$340K	$0	N/A
Total Equity	$6.0M+4.3%	$5.7M+97.9%	$2.9M-74.9%	$11.5M-43.4%	$20.4M+584.6%	-$4.2M
Retained Earnings	-$41.5M-19.8%	-$34.7M-28.6%	-$27.0M-58.6%	-$17.0M-120.9%	-$7.7M-82.9%	-$4.2M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$11.5M+80.1%	$5.6M+6.1%	$7.1M+6.9%	$4.9M-41.5%	$6.4M-41.0%	$5.3M+4.0%	$6.7M+36.7%	$8.4M+1.3%
Current Assets	$9.8M+106.7%	$4.0M+11.1%	$5.5M+11.5%	$3.4M-48.9%	$4.7M-47.3%	$3.6M+3.5%	$4.9M+52.1%	$6.6M+0.6%
Cash & Equivalents	$9.6M+116.0%	$3.7M+18.2%	$5.2M+20.1%	$3.1M-46.4%	$4.4M-44.9%	$3.1M+17.1%	$4.3M+94.8%	$5.8M+13.4%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$2.1M+90.4%	$1.4M+0.4%	$1.1M+23.3%	$1.2M+0.7%	$1.1M-49.8%	$1.4M-17.3%	$928K-53.0%	$1.2M-60.8%
Current Liabilities	$2.1M+103.3%	$1.4M+7.4%	$1.1M+38.1%	$1.1M+9.5%	$1.0M-49.4%	$1.3M-13.7%	$810K-54.3%	$1.0M-62.5%
Non-Current Liabilities	$2K-96.6%	$3K-96.3%	$25K-78.9%	$49K-65.2%	$72K-55.4%	$95K-47.9%	$118K-41.9%	$140K-40.1%
Total Equity	$9.4M+78.0%	$4.2M+8.1%	$6.0M+4.3%	$3.7M-48.5%	$5.3M-38.8%	$3.9M+14.8%	$5.7M+97.9%	$7.2M+37.4%
Retained Earnings	-$45.8M-18.9%	-$43.4M-18.9%	-$41.5M-19.8%	-$40.1M-20.6%	-$38.5M-21.2%	-$36.5M-24.8%	-$34.7M-28.6%	-$33.2M-34.8%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

BJDX Cash Flow Statement

BJDX quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Operating Cash Flow	-$5.9M	-$6.1M+22.6%	-$7.8M+5.9%	-$8.3M-7.4%	-$7.7M-77.3%	-$4.4M-758.4%	-$509K
Depreciation & Amortization	N/A	$74K-1.9%	$76K-88.3%	$649K+314.3%	$157K+7.5%	$146K-7.2%	$157K
Stock-Based Compensation	N/A	$6-100.0%	$20K-89.4%	$189K-56.3%	$433K+532.5%	$68K+1735.3%	$4K
Capital Expenditures	N/A	$174K-43.4%	$307K-56.4%	$704K-41.3%	$1.2M+4908.0%	$24K	N/A
Free Cash Flow	N/A	-$6.2M+23.4%	-$8.1M+9.9%	-$9.0M-0.9%	-$8.9M-103.6%	-$4.4M	N/A
Investing Cash Flow	N/A	-$174K+43.4%	-$307K+56.4%	-$704K+41.3%	-$1.2M-4908.0%	-$24K	N/A
Financing Cash Flow	$11.4M	$7.1M-30.6%	$10.2M+819.5%	$1.1M+13665.5%	$8K-100.0%	$22.5M+1600.0%	$1.3M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$1.5M+27.0%	-$1.6M-34.1%	-$1.5M-0.2%	-$1.4M+36.9%	-$2.1M-7.3%	-$1.2M+48.5%	-$1.5M+47.7%	-$2.2M-91.5%
Depreciation & Amortization	$28K+58.9%	$28K+50.9%	$27K+38.6%	$11K-39.9%	$18K-3.9%	$18K-6.7%	$20K-11.5%	$18K-93.0%
Stock-Based Compensation	N/A	N/A	N/A	$183-96.2%	-$2K-126.0%	$1K-89.0%	N/A	$5K+111.3%
Capital Expenditures	$143K	$19K	N/A	N/A	N/A	N/A	$1K-98.7%	$227-99.7%
Free Cash Flow	-$1.6M	-$1.6M	N/A	N/A	N/A	N/A	-$1.5M+49.3%	-$2.2M-79.6%
Investing Cash Flow	-$143K	-$15K	N/A	N/A	N/A	N/A	-$1K+98.7%	-$227+99.7%
Financing Cash Flow	$7.6M+123.5%	$124K+12698.6%	$3.7M+279980.2%	-$1K+99.3%	$3.4M-55.4%	-$985-100.0%	-$1K+56.5%	-$148K-112.6%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

BJDX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BJDX quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Gross Margin	N/A	N/A	N/A	19.6%	N/A	N/A
Operating Margin	N/A	N/A	N/A	-3741.5%	N/A	N/A
Net Margin	N/A	N/A	N/A	-3733.1%	N/A	N/A
Return on Equity	-114.6%+20.1pp	-134.7%+209.1pp	-343.8%-263.3pp	-80.5%-63.4pp	-17.1%	N/A
Return on Assets	-96.2%+19.7pp	-115.9%+88.5pp	-204.5%-135.7pp	-68.8%-52.2pp	-16.6%+59.7pp	-76.3%
Current Ratio	4.88-1.2x	6.05+4.2x	1.82-5.4x	7.19-25.2x	32.43	N/A
Debt-to-Equity	0.190.0x	0.16-0.5x	0.68+0.5x	0.17+0.1x	0.03	N/A
Asset Turnover	N/A	N/A	N/A	0.02	N/A	N/A
FCF Margin	N/A	N/A	N/A	-3590.1%	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Return on Equity	-24.7%+12.3pp	-45.9%+2.3pp	N/A	-43.3%-22.6pp	-37.0%-8.3pp	-48.2%+20.9pp	N/A	-20.7%+23.4pp
Return on Assets	-20.2%+10.4pp	-34.3%+1.0pp	N/A	-32.7%-14.9pp	-30.6%-7.8pp	-35.3%+10.6pp	N/A	-17.7%+10.1pp
Current Ratio	4.64+0.1x	2.81+0.1x	4.88-1.2x	2.92-3.3x	4.56+0.2x	2.71+0.5x	6.05+4.2x	6.26+3.9x
Debt-to-Equity	0.230.0x	0.340.0x	0.190.0x	0.32+0.2x	0.210.0x	0.37-0.1x	0.16-0.5x	0.17-0.4x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Bluejay Diagnostics, Inc. BJDX	FY2025	N/A	-$6.8M	N/A	$928K	—
AETHLON MEDICAL INC AEMD	FY2026	N/A	-$7.2M	N/A	$1.1M	—
Catheter Precision, Inc. VTAK	FY2025	$819K	-$17.2M	N/A	$632K	—
Nuwellis, Inc. NUWE	FY2025	$8.3M	-$17.5M	N/A	$2.5M	45/100
Bone Biologics Corp BBLG	FY2025	N/A	-$3.1M	N/A	$1.5M	—
Tivic Health Systems, Inc. TIVC	FY2025	N/A	-$8.9M	N/A	$4.0M	—

Where Bluejay Diagnostics, Inc. Ranks

Frequently Asked Questions

Is Bluejay Diagnostics, Inc. profitable?

No, Bluejay Diagnostics, Inc. (BJDX) reported a net income of -$6.8M in fiscal year 2025.

What is Bluejay Diagnostics, Inc.'s EBITDA?

Bluejay Diagnostics, Inc. (BJDX) had EBITDA of -$6.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Bluejay Diagnostics, Inc.'s return on equity (ROE)?

Bluejay Diagnostics, Inc. (BJDX) has a return on equity of -114.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Bluejay Diagnostics, Inc.'s free cash flow?

Bluejay Diagnostics, Inc. (BJDX) recorded an outflow of $6.2M in free cash flow during fiscal year 2025. This represents a 23.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Bluejay Diagnostics, Inc.'s operating cash flow?

Bluejay Diagnostics, Inc. (BJDX) recorded an outflow of $6.1M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Bluejay Diagnostics, Inc.'s total assets?

Bluejay Diagnostics, Inc. (BJDX) had $7.1M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Bluejay Diagnostics, Inc.'s capital expenditures?

Bluejay Diagnostics, Inc. (BJDX) invested $174K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Bluejay Diagnostics, Inc. spend on research and development?

Bluejay Diagnostics, Inc. (BJDX) invested $3.0M in research and development during fiscal year 2025.

How many shares does Bluejay Diagnostics, Inc. have outstanding?

Bluejay Diagnostics, Inc. (BJDX) had 972,215 shares outstanding as of fiscal year 2025.

What is Bluejay Diagnostics, Inc.'s current ratio?

Bluejay Diagnostics, Inc. (BJDX) had a current ratio of 4.88 as of fiscal year 2025, which is generally considered healthy.

What is Bluejay Diagnostics, Inc.'s debt-to-equity ratio?

Bluejay Diagnostics, Inc. (BJDX) had a debt-to-equity ratio of 0.19 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Bluejay Diagnostics, Inc.'s return on assets (ROA)?

Bluejay Diagnostics, Inc. (BJDX) had a return on assets of -96.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Bluejay Diagnostics, Inc.'s P/E ratio?

Bluejay Diagnostics, Inc. (BJDX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $928K as of Sep 12, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Bluejay Diagnostics, Inc.'s price-to-sales ratio?

Bluejay Diagnostics, Inc. (BJDX) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $928K as of Sep 12, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Bluejay Diagnostics, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Bluejay Diagnostics, Inc. (BJDX) held $5.2M in cash, cash equivalents and investments, and reported an operating cash outflow of $6.1M over that year. Dividing the one by the other, the reported balance equals about 10 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Bluejay Diagnostics, Inc.'s Piotroski F-Score?

Bluejay Diagnostics, Inc. (BJDX) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Bluejay Diagnostics, Inc.'s earnings high quality?

Bluejay Diagnostics, Inc. (BJDX) reported a net loss of $6.8M while operations used $6.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Bluejay Diagnostics, Inc. cover its interest payments?

Bluejay Diagnostics, Inc. (BJDX) reported an operating loss of $7.0M against $839 in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.